BR112022026265A2 - Métodos e composições para tratar hemofilia - Google Patents
Métodos e composições para tratar hemofiliaInfo
- Publication number
- BR112022026265A2 BR112022026265A2 BR112022026265A BR112022026265A BR112022026265A2 BR 112022026265 A2 BR112022026265 A2 BR 112022026265A2 BR 112022026265 A BR112022026265 A BR 112022026265A BR 112022026265 A BR112022026265 A BR 112022026265A BR 112022026265 A2 BR112022026265 A2 BR 112022026265A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- hemophilia
- treat hemophilia
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042390P | 2020-06-22 | 2020-06-22 | |
| PCT/US2021/038445 WO2021262695A1 (en) | 2020-06-22 | 2021-06-22 | Methods and compositions for treating hemophilia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026265A2 true BR112022026265A2 (pt) | 2023-01-17 |
Family
ID=76943130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026265A BR112022026265A2 (pt) | 2020-06-22 | 2021-06-22 | Métodos e composições para tratar hemofilia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210393669A1 (https=) |
| EP (1) | EP4168018A1 (https=) |
| JP (1) | JP2023531679A (https=) |
| KR (1) | KR20230027277A (https=) |
| CN (1) | CN115942940A (https=) |
| AU (1) | AU2021296786A1 (https=) |
| BR (1) | BR112022026265A2 (https=) |
| CA (1) | CA3188137A1 (https=) |
| IL (1) | IL299295A (https=) |
| MX (1) | MX2023000164A (https=) |
| TW (1) | TW202216172A (https=) |
| WO (1) | WO2021262695A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240075001A1 (en) * | 2022-05-24 | 2024-03-07 | Darren Rubin | Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients |
| US20240000744A1 (en) * | 2022-06-08 | 2024-01-04 | Genzyme Corporation | Treatment of Hemophilia with Fitusiran |
| CN118460655B (zh) * | 2024-07-10 | 2025-01-28 | 凯莱英医药集团（天津）股份有限公司 | 抑制FXI基因表达的siRNA的制备方法 |
| WO2026012399A1 (zh) * | 2024-07-10 | 2026-01-15 | 正大天晴药业集团股份有限公司 | 靶向serpinc1的双链核糖核酸 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| TW202434265A (zh) * | 2017-07-10 | 2024-09-01 | 美商健贊公司 | 於患有血友病之個體中治療出血事件之方法及組成物 |
-
2021
- 2021-06-22 CA CA3188137A patent/CA3188137A1/en active Pending
- 2021-06-22 JP JP2022578970A patent/JP2023531679A/ja active Pending
- 2021-06-22 MX MX2023000164A patent/MX2023000164A/es unknown
- 2021-06-22 WO PCT/US2021/038445 patent/WO2021262695A1/en not_active Ceased
- 2021-06-22 AU AU2021296786A patent/AU2021296786A1/en active Pending
- 2021-06-22 US US17/354,818 patent/US20210393669A1/en not_active Abandoned
- 2021-06-22 CN CN202180044790.1A patent/CN115942940A/zh active Pending
- 2021-06-22 TW TW110122791A patent/TW202216172A/zh unknown
- 2021-06-22 EP EP21742607.1A patent/EP4168018A1/en active Pending
- 2021-06-22 BR BR112022026265A patent/BR112022026265A2/pt unknown
- 2021-06-22 KR KR1020237002631A patent/KR20230027277A/ko active Pending
-
2022
- 2022-12-20 IL IL299295A patent/IL299295A/en unknown
-
2025
- 2025-09-17 US US19/331,354 patent/US20260014188A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021262695A1 (en) | 2021-12-30 |
| KR20230027277A (ko) | 2023-02-27 |
| JP2023531679A (ja) | 2023-07-25 |
| MX2023000164A (es) | 2023-07-06 |
| TW202216172A (zh) | 2022-05-01 |
| AU2021296786A1 (en) | 2023-02-23 |
| CN115942940A (zh) | 2023-04-07 |
| IL299295A (en) | 2023-02-01 |
| CA3188137A1 (en) | 2021-12-30 |
| US20260014188A1 (en) | 2026-01-15 |
| US20210393669A1 (en) | 2021-12-23 |
| EP4168018A1 (en) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026265A2 (pt) | Métodos e composições para tratar hemofilia | |
| BR112022019932A2 (pt) | Composições para saúde metabólica | |
| BR112013028666A2 (pt) | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo | |
| BRPI0808746B8 (pt) | derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila. | |
| CL2018000293A1 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
| BR112015013105A2 (pt) | composições de irna de pcsk9 e métodos de uso das mesmas | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2009010122A (es) | Derivados de purinilo y su uso como moduladores del canal de potasio. | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| MX2010001692A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| JOP20230157A1 (ar) | طرق مُعالجة فيروس كورونا | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| BR112017017109A2 (pt) | novo triterpenone c-3 com derivados amidos reversos c-28 como inibidores de hiv | |
| CO2025013790A2 (es) | Compuestos heterocíclicos como inhibidores de wrn | |
| CY1120906T1 (el) | Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου | |
| CL2011002160A1 (es) | Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
| ES2380951T3 (es) | Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH | |
| BR112022008938A2 (pt) | Derivados de 1-aminossulfonil-2-carboxipirrol como inibidores de metalo-beta-lactamase | |
| BR112022024754A2 (pt) | Composições e métodos para tratar covid longo | |
| WO2020049552A9 (en) | Tissue repair by activated cells | |
| BR112022016803A2 (pt) | População de linfócitos e métodos para produzir os mesmos |